Although the exact mechanism is still unknown, SGLT2i seem to regulate autophagy and reduce DKD progression through molecular pathways that primarily involve the AMPK and mechanistic target of rapamycin (mTOR) signaling pathways, further reducing tubular and glomerular damage [140,200,201,202,203,204]. The gene discussed is MTOR; the disease is diabetic kidney disease.